Jiangsu Hengrui Medicine Co., Ltd.
https://www.hrs.com.cn/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jiangsu Hengrui Medicine Co., Ltd.
Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tecentriq Combo A New Weapon As China Tackles HCC
With the country accounting for 50% of global liver cancer cases, China aims the crosshairs with the help of novel therapies.
Trump Or Biden, China Determined To Narrow Health Gap With US
Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.
Affordable PD-1 From China? CStone Going Global With EQRx Onboard
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Hengrui Therapeutics, Inc.